Abstract
Objective This study examined the laboratory results of COVID-19 patients from a hospital in the Peruvian Amazon and their clinical prognosis.
Methods An analytical cross-sectional study was carried out whose purpose was to identify the laboratory tests of patients with COVID-19 and mortality in a hospital in Ucayali, Peru during the period from March 13 to May 9, 2020, selecting a total of 127 with Covid-19. Mean and the standard deviation was described for age, leukocytes, neutrophils, platelets, RDW-SD; median and interquartile range for the variables lymphocyte, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils.
Results No differences were observed in this population regarding death and sex (OR: 1.31; 95% CI 0.92 to 1.87), however, it was observed that, for each one-year increase, the probability of death increased by 4% (PR: 1.04, 95% CI 1.03 to 1.05). The IRR (Incidence Risk Ratio) analysis for the numerical variables showed results strongly associated with hematological values such as Leukocytes (scaled by 2500 units) (IRR: 1.08, 95% CI 1.03 to 1.13), neutrophils (scaled by 2500 units) (IRR: 1.08; 95% CI 1.03 to 1.13), on the contrary, it is observed that the increase of 1000 units in lymphocytes, the probability of dying decreased by 48% (IRR: 0.52; 95% CI 0.38 to 071).
Conclusion Parameters such as leukocytes and neutrophils were statistically much higher in patients who died.
INTRODUCTION
The COVID-19 pandemic is caused by a beta coronavirus initially called 2019-nCoV or occasionally HCoV-19 and definitively named SARS-CoV-2(1). This coronavirus causes an acute respiratory syndrome that was isolated for the first time in Wuhan, China, it is believed to be of zoonotic origin, that is, it was transmitted from an animal host to a human one(2). The genome of this virus is made up of positive single-stranded RNA, this can cause transmission from person to person through drops of saliva (3). This new zoonotic virus has put the world on alert, rapidly becoming a pandemic, clinical findings in patients are important in the prognosis of the patient.
The clinical characteristics of COVID-19 are very diverse but can be arranged into four categories: systemic, respiratory, gastrointestinal, and cardiovascular (4). There are a wide number of symptoms in patients with COVID-19, only six symptoms occurred in 50% of people such as cough, sore throat, fever, myalgia or arthralgia, fatigue, and headache(5,6). Of these, fever, myalgia or arthralgia, fatigue, and headache could be considered red flags (4). Loss of smell taste is a highly specific symptom of COVID-19 (7). Knowing the specific symptoms for COVID-19 does not help to have a quick diagnosis, better follow-up, and prognosis of infected patients.
The main cause of death is respiratory failure due to acute respiratory distress syndrome (8). The overall combined mortality rate from respiratory failure in COVID-19 patients is discharged; however, this varies significantly between countries (9). People younger than 65 have a very small risk of death even in the epicenters of a pandemic, and deaths in people younger than 65 without any underlying conditions are rare. (10). The prognosis of patients with COVID-19 can be affected by comorbidities such as diabetes,(11) hypertension, stroke, cancer, kidney disease, and high cholesterol (12). Risk factors should be considered to avoid rapid progression and poor prognosis of COVID-19 disease. More attention should be paid to these patients, in case of rapid deterioration.
Laboratory medicine is of great help for the early detection of SARS-CoV-2 and allows us to discriminate between patients with severe and non-severe COVID-19 (13). Findings in COVID-19 patients will help better understand key disease traits and could be used for future disease research, control, and prevention (14). COVID-19 has a significant impact on the hematopoietic system and hemostasis (15). Leukocytosis, lymphopenia, and thrombocytopenia are associated with increased severity and even death in COVID-19 cases(16). Lymphopenia can be considered as a key laboratory finding, with prognostic potential (15). A significant decrease in peripheral CD4 + and CD8 + T lymphocytes was observed (17). These findings are important to know the prognosis of patients with COVID-19.
There are still questions to be resolved about COVID-19, it is with us a short time, which is a short time to give accurate details about it, that is why it is necessary to increase research in all fields of science, to help us fight the pandemic and get back to the new normal. This study examined the laboratory results of COVID-19 patients from a hospital in the Peruvian Amazon and their clinical prognosis.
METHODS
Study design
An analytical cross-sectional study was carried out, the purpose of which was to identify the laboratory tests of patients with COVID-19 and mortality in a hospital in Ucayali (located in the Central Jungle, in eastern Peru).
Population and sample
The population consisted of hospitalized patients with a confirmed diagnosis of COVID-19 in a hospital in Ucayali, Peru during the period from March 13 to May 9, 2020, selected a total of 127 people consecutively.
Procedures
The diagnosis of COVID-19 was made based on the provisional guidelines of the World Health Organization (WHO)(18). A confirmed case of Covid-19 was defined as a positive result in the polymerase chain reaction-transcriptase (RT-PCR) assay of nasopharyngeal swab samples and rapid immunochromatographic test. The only laboratory-confirmed cases were included in the analysis. Follow-up was carried out until discharge or death.
The laboratory tests were performed within the hospital headquarters at the time of admission, these were corroborated by a pathologist. All the laboratory tests were carried out following the clinical care needs of the patient following the technical standard of the Ministry of Health of Peru. Laboratory evaluations consisted of leukocytes, neutrophils, platelets, RDW-SD, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils.
Statistical analysis
Statistical analysis was performed in the STATA v.16.1 software (StataCorp LP, College Station, TX, USA). Mean and the standard deviation was described for age, leukocytes, neutrophils, platelets, RDW-SD; median and interquartile range for the variables lymphocyte, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils; the variables sex, ICU, and death were reported as frequencies and percentages.
In the bivariate analysis of categorical variables, the chi-square test was used to explore the association between laboratory factors and COVID-19 mortality, after evaluating the assumption of expected frequencies. For the numerical variables, the student’s t-test was used for independent samples, or the Mann Whitney U test according to the normality distribution. In the simple regression analysis, prevalence ratios and 95% confidence intervals were estimated, using the Poisson distribution family, log link function, and robust variance. For the multiple models, a parsimonious model was built by performing a nesting process between the variables that were found to contribute significantly to the model, using the Likelihood-ratio test.
The area under the curve (AUC) values with their 95% confidence intervals of the hematological variables were calculated for the prediction of mortality.
Ethical aspects
This research has been approved by the Ethics Committee of the National University of Ucayali. Codes were used to maintain the confidentiality of data for COVID-19 patients eligible for this study. The ethical principles of the Declaration of Helsinki were respected.
RESULTS
Information was collected from 127 people from Hospital II Essalud Pucallpa. It is a population with an average age of 59.6 years, where the female sex predominated (67.72%). Of this population, it was found that 21 (83.46 %) patients were in the ICU, also the entire population had a mortality of 75 people (59.06 %).
Regarding the laboratory tests, it is observed that, on average, the general population had high levels of biochemical and hematological values. However, when stratifying according to mortality, the parameters such as leukocytes and neutrophils were statistically much higher in patients who died (p <0.001 in both cases), also, those who died had lymphocytopenia compared to normal values in survivors (720 vs 1360 respectively, p <0.001), something similar happened with monocytes and eosinophils.
It can be seen that in other parameters such as RN / L, fibrinogen among others, they were higher in the population that died compared to the one that survived. Platelet, RDW-SD, and D-dimer values were statistically similar in both groups. See Table 1.
No differences were observed in this population regarding death and sex (OR: 1.31; 95% CI 0.92 to 1.87), however, it was observed that, for each one-year increase, the probability of death increased by 4% (PR: 1.04, 95% CI 1.03 to 1.05). The IRR (Incidence Risk Ratio) analysis for the numerical variables showed results strongly associated with hematological values such as Leukocytes (scaled by 2500 units) (IRR: 1.08, 95% CI 1.03 to 1.13), neutrophils (scaled by 2500 units) (IRR: 1.08; 95% CI 1.03 to 1.13), on the contrary, it is observed that the increase of 1000 units in lymphocytes, the probability of dying decreased by 48% (IRR: 0.52; 95% CI 0.38 to 071). It is worth mentioning that the one with the greatest strength of association was the D-dimer since for each 1 mg / L increase in D-dimer, the risk of dying increased by 25% (IRR: 1.25, 95% CI 1.10 to 1.43). The other results are shown in Table 2.
In the explanatory variables model, it was observed that D-dimer and lymphocytes (scaled by 1000 units) had a strong association with mortality (IRR: 1.18 and 0.22 respectively), neutrophils (scaled by 2500 units) had a marginal association (IRR: 1.08, 95% CI: 0.99 to 1.17). See Table 2.
These results were complemented with the search for the area under the curve (AUC), where it was found that fibrinogen had the best AUC (AUC: 82.5%, 95% CI 72.17 to 92.83), followed by RN / L with AUC: 79.01 %. These and other variables can be seen in table 3 and figure 1.
DISCUSSION
We look at the clinical symptoms of 127 COVID-19 patients, here, we mainly analyze and summarize the laboratory tests of COVID-19 patients, especially the biochemical and hematological parameters. In our study, the laboratory tests of the general population studied that was infected by SARS-CoV-2 had high levels of biochemical and hematological values, these findings have also been found in other systematic reviews of patients with COVID-19 and SARS(16,19,20). These findings can be explained why the blood presents a state of hypercoagulation, which becomes more acute in critically ill patients. (21). Our results show important biochemical and hematological changes in patients with COVID-19.
It was found that the parameters such as leukocytes and neutrophils were statistically much higher in patients who died (p <0.001 in both cases), these risk factors related to immunity can predict the mortality of patients with COVID-19 (22). Patients who died presented lymphocytopenia compared to normal values in survivors (720 vs 1360 respectively, p <0.001), something similar happened with monocytes and eosinophils. Lymphocytopenia is an independent risk factor for hospital mortality for COVID-19 patients, especially men(23). Risk factors related to the mortality of patients with COVID-19 were found such as increased leukocytes and neutrophils along with lymphocytopenia, the evaluation of these parameters can help to identify people at high risk with COVID-19.
It can be seen that in other parameters such as the neutrophil-lymphocyte ratio (RN / L), fibrinogen among others, they were higher in the population that died compared to the one that survived. Elevated fibrinogen level has been considered an epiphenomenon of pulmonary edema rather than activation of coagulation in affected patients(24). Platelet values, red cell distribution width with standard deviation (RDW-SD), and D-dimer were statistically similar in both groups. There are findings in which an increase in D-dimer levels is found and this increases according to the severity in patients with COVID-19 (24,25). RDW-SD was a predictor in the group of severe patients in which its values were significantly higher than those of the group of patients with moderate COVID-19 (26).
In this study, it was observed that, for each one-year increase, the probability of dying increased by 4%, these results have been reported in other studies (27). It is worth mentioning that the one who presented the greatest strength of association was D-dimer, since for every 1 mg / L increase in D-dimer, the risk of dying increased by 25%, these high values are associated in those with severe disease(28).
We conclude that the laboratory tests, it is observed that, on average, the general population had high levels of biochemical and hematological values. Parameters such as leukocytes and neutrophils were statistically much higher in patients who died.
Data Availability
The information is clinical data that should not be disclosed.
Footnotes
Conflict of interest: the authors declare that they have no conflict of interest.
Financing: self-financed.
sebasiglo{at}gmail.com, arturorafaelheredia{at}gmail.com, ericrojastello{at}hotmail.com, wou03{at}hotmail.com, waroleveau{at}gmail.com, orisonleveau{at}hotmail.com, ammimbela{at}gmail.com, lizbeth_cordova{at}unj.edu.pe, ellop2424{at}hotmail.com, virgiliofr{at}gmail.com